News Sentiment

BRNS sentiment intelligence

Barinthus Biotherapeutics plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.56 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-12.9% over one week, -16.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Barinthus Biotherapeutics (NasdaqCM:BRNS) Stock Price

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -12.9% Price reacting lower
Trend fit Trend inactive -16.1% over four weeks
Fair value -63.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 31
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
TradingKey 8
Market source 7
Stock Titan 6
dars.gov.et 3
simplywall.st 2
MarketBeat 2
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 16
Deals and strategy 3
Analyst action 2
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-44 of 44
TradingView Direct company coverage

Barinthus Biotherapeutics plc. 1Q 2026: Revenue ($8.37M), Net income ($5.53M), EPS ($0.14) — 10-Q Summary

Barinthus Biotherapeutics plc. reported its first-quarter 2026 results, showing a significant reduction in comprehensive and net loss compared to the previous year. The company is focusing its pipeline on immunology & inflammation, unwinding other programs, and plans an all-stock

Tone
Neutral 50/100
Event
Earnings
Published
05 May 2026 00:10
Source
TradingView
Market source Direct company coverage

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

Barinthus Bio reported its first quarter 2026 financial results, highlighting a progressing proposed combination with Clywedog Therapeutics Inc. that is expected to close mid-2026. The merged entity will focus on metabolic and autoimmune pipeline assets, including Barinthus Bio's

Tone
Positive 70/100
Event
Earnings
Published
02 May 2026 11:09
Source
Market source
TradingView Direct company coverage

Barinthus Biotherapeutics PLC expected to post a loss of 28 cents a share - Earnings Preview

Barinthus Biotherapeutics PLC (BRNS) is expected to announce an earnings loss of 28 cents per share. This information comes from a Reuters earnings preview. The article provides a brief outlook on the company's anticipated financial performance, indicating it will be reporting a

Tone
Negative 28/100
Event
Earnings
Published
01 May 2026 22:39
Source
TradingView
Stock Titan Direct company coverage

Barinthus Biotherapeutics (NASDAQ: BRNS) files Form 3 for Principal Accounting Officer

Barinthus Biotherapeutics (NASDAQ: BRNS) has filed a Form 3, an initial statement of beneficial ownership, for Douglas J. Swirsky, who has been appointed as the Principal Accounting Officer. This filing establishes his executive officer status but indicates no reportable share tr

Tone
Neutral 50/100
Event
Market update
Published
01 May 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Merger and trial plans shape Barinthus Bio (NASDAQ: BRNS) outlook

Barinthus Bio reported a first-quarter 2026 net loss of $5.5 million, significantly improving from the prior year, driven by reduced operating expenses and a refocused portfolio. The company is advancing a proposed merger with Clywedog Therapeutics, expected to close mid-2026, wh

Tone
Positive 63/100
Event
Deals and strategy
Published
30 Apr 2026 11:38
Source
Stock Titan